Surgical resection is a principal treatment modality in the early stages of non-small cell lung cancer. The risks of surgical procedures are decreasing due to advancements in surgical techniques. However, optimal treatment strategy in locally advanced stages is unclear. Neoadjuvant immunotherapy could be a future treatment alternative.

Citace poskytuje Crossref.org